ArticleClinical epidemiology2026
Cause-Specific Mortality in Gastroesophageal Cancer: A 30-Year Real-World Analysis from the Vienna Gastroesophageal Cancer Database.
Article in Clinical epidemiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Despite therapeutic advances, gastroesophageal cancers remain associated with high mortality. While most deaths are cancer-related, improvements in therapy and supportive care may alter mortality patterns over time. This study aimed to characterize causes of death and associated clinical factors in a large real-world European cohort. Methods: We retrospectively included 2518 patients with histologically confirmed esophageal, gastric, or gastroesophageal junction carcinomas treated at the Medical University of Vienna between 1994 and 2024. Causes of death were obtained from Austria's national death registry and categorized using International Classification of Diseases (ICD) codes. Fine-Gray competing risk models were applied to identify factors associated with cancer- and non-cancer-related deaths. Results: At data cutoff, 1863 patients (74%) had died. Of these, 85% of deaths were cancer-related, 12% non-cancer-related, 2% unknown, and <1% suicide. Tumor stage was the strongest predictor of cancer-related mortality, with subdistribution hazard ratios (sHR) increasing from 2.34 (95% CI 1.91-2.86) in stage 2 to 7.42 (95% CI 6.15-8.96) in stage 4 disease compared with stage 1 (all p < 0.001). A higher comorbidity burden also independently increased cancer-related mortality. Non-cancer-related death was primarily associated with older age (≥65 years; sHR 2.21, 95% CI 1.12-4.35, p = 0.021) and stomach tumor location (sHR 1.56, 95% CI 1.08-2.23, p = 0.017), while more recent diagnosis (2020-2024) was linked to a lower risk of both cancer- and non-cancer-related mortality (cancer-related: sHR 0.60, 95% CI 0.47-0.76, p < 0.001; non-cancer-related: sHR 0.43, 95% CI 0.25-0.74, p = 0.002), likely reflecting a combination of evolving treatment strategies, improvements in supportive care, and shorter follow-up in the most recent cohort. Conclusion: Cancer progression remains the predominant cause of death in patients with gastroesophageal cancer, with tumor stage as the key prognostic factor. These high mortality rates emphasize the need for improved antitumoral treatment and timely palliative care approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.